{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:01:12Z","timestamp":1765076472501,"version":"3.46.0"},"reference-count":36,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,1,18]]},"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To conduct the benefit\u2013risk assessment of 3-hydroxy-3-methyl-glutaryl (HMG) coenzyme A reductase inhibitors (statins) using a discrete choice experiment, based on 3 major stakeholders\u2019 perspectives including patients, experts and policymakers in Thailand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A discrete choice experiment questionnaire survey in three stakeholders\u2019 perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Public hospitals in Thailand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 353 policymakers, experts and patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Stakeholders\u2019 preferences for assessment criteria (stroke reduction, myocardial infarction reduction, myalgia and hepatotoxicity). Statins\u2019 ranking and maximum acceptable risk in all perspectives were also calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For any perspective, the most and least important criteria were the risk of hepatotoxicity and the benefit of myocardial infarction reduction, respectively. Patients and experts agreed on the order of importance for myalgia and stroke reduction, but policymakers had different order of importance in these criteria. Overall, results showed that the highest and lowest chances of being chosen were atorvastatin and rosuvastatin, respectively. Only patients\u2019 ranking order was different from others. Maximum acceptable risk of hepatotoxicity was lower than that of myalgia, reflecting the greater concern of all perspectives to statin consequence on liver.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of benefit\u2013risk assessment from every perspective were somewhat consistent. This study demonstrated the feasibility of applying a discrete choice experiment in the benefit\u2013risk assessment of drugs and encouraged the engagement of multiple stakeholders in the decision-making process.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-009387","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T22:19:04Z","timestamp":1456438744000},"page":"e009387","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Benefit\u2013risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-8062","authenticated-orcid":false,"given":"Tanatape","family":"Wanishayakorn","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai, Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Korn","family":"Sornlertlumvanich","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai, Songkhla, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surachat","family":"Ngorsuraches","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai, Songkhla, Thailand"},{"name":"Department of Pharmacy Practice, College of Pharmacy, South Dakota State University, Brookings, South Dakota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"key":"2025120618151337000_6.2.e009387.1","unstructured":"Bureau of drug control, Thailand's Food and Drug Administration (FDA). The cost of manufactured and imported drugs in Thailand from 1987 to 2012. http:\/\/drug.fda.moph.go.th\/zone_search\/files\/sea001_001.asp (accessed 23 Oct 2015)."},{"key":"2025120618151337000_6.2.e009387.2","first-page":"40","article-title":"Cost of adverse drug reactions (ADRs) induced hospitalization: a systematic review","volume":"40","author":"Siltharm","year":"2013","journal-title":"Mahidol Univ J Pharm Sci"},{"issue":"(Suppl 1)","key":"2025120618151337000_6.2.e009387.3","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jval.2011.11.002","article-title":"Drug reimbursement decision-making in Thailand, China, and South Korea","volume":"15","author":"Ngorsuraches","year":"2012","journal-title":"Value Health"},{"key":"2025120618151337000_6.2.e009387.4","first-page":"18","article-title":"ISafE and the evidence-based approach for essential medicines selection in Thailand","volume":"34","author":"Chongtrakul","year":"2005","journal-title":"Essent Drugs Monit"},{"key":"2025120618151337000_6.2.e009387.5","unstructured":"Egbrink MO . Patient involvement in benefit-risk assessment at the European Medicines Agency: a patient-informed analysis to determine the room for improvement by using quantitative patient preferences [master's thesis]. Netherland: University of Twente, Faculty of Behavioural, Management & Social Sciences, 2013."},{"key":"2025120618151337000_6.2.e009387.6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.12688\/f1000research.2-160.v1","article-title":"Systematic assessment of benefits and risks: study protocol for a multi-criteria decision analysis using the Analytic Hierarchy Process for comparative effectiveness research","volume":"2","author":"Maruthur","year":"2013","journal-title":"F1000Res"},{"key":"2025120618151337000_6.2.e009387.7","unstructured":"European Medicines Agency. Benefit-risk methodology project: Work Package 2 Report: Applicability of current tools and processes for regulatory benefit-risk assessment. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/10\/WC500097750.pdf (accessed 25 Oct 2015)."},{"key":"2025120618151337000_6.2.e009387.8","unstructured":"Ngorsuraches S , Paannahrungsee P , Wanishayakorn T . Civil servant medical beneficiaries\u2019 preference and willingness-to-pay for medications: a case study of HMG-CoA reductase inhibitors (statins). http:\/\/kb.hsri.or.th\/dspace\/handle\/11228\/3762 (accessed 25 Oct 2015)."},{"key":"2025120618151337000_6.2.e009387.9","unstructured":"Intercontinental Marketing Services. Thailand Healthcare Index Report 2008, IMS Health Thailand: Bangkok, 2009."},{"key":"2025120618151337000_6.2.e009387.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00725.x"},{"key":"2025120618151337000_6.2.e009387.11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.joca.2012.11.007","article-title":"A discrete-choice experiment of United Kingdom patients\u2019 willingness to risk adverse events for improved function and pain control in osteoarthritis","volume":"221","author":"Hauber","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"2025120618151337000_6.2.e009387.12","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/ar4465","article-title":"Patients\u2019 preferences for osteoporosis drug treatment: a discrete-choice experiment","volume":"16","author":"Hiligsmann","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025120618151337000_6.2.e009387.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00694.x"},{"key":"2025120618151337000_6.2.e009387.14","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826080-00004"},{"key":"2025120618151337000_6.2.e009387.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"2025120618151337000_6.2.e009387.16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"2025120618151337000_6.2.e009387.17","doi-asserted-by":"publisher","DOI":"10.1177\/2047487313480435"},{"key":"2025120618151337000_6.2.e009387.18","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hct041"},{"key":"2025120618151337000_6.2.e009387.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.624890"},{"key":"2025120618151337000_6.2.e009387.20","unstructured":"DRUGDEX\u00ae System [database on the Internet]. Greenwood Village, CO: Truven Health Analytics, 2013. http:\/\/www.micromedexsolutions.com (accessed 23 Oct 2015)."},{"key":"2025120618151337000_6.2.e009387.21","unstructured":"Novak KK, managing ed. Drug facts and comparisons. St. Louis, MO: Wolters Kluwer Health Inc., 2012:536\u20139."},{"key":"2025120618151337000_6.2.e009387.22","unstructured":"Corbett AH , Dana WJ , Fuller MA , et al . Drug information handbook. 23rd edn. Hudson, OH: Lexi-Comp, Inc, 2014:191\u20131900."},{"key":"2025120618151337000_6.2.e009387.23","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1435"},{"key":"2025120618151337000_6.2.e009387.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00670.x"},{"key":"2025120618151337000_6.2.e009387.25","unstructured":"Orme BK . Getting started with conjoint analysis: strategies for product design and pricing research. 2nd edn. Madison, WI: Research Publishers LLC, 2010:57\u201366."},{"key":"2025120618151337000_6.2.e009387.26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq072"},{"key":"2025120618151337000_6.2.e009387.27","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000140782.04973.D9"},{"key":"2025120618151337000_6.2.e009387.28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.2042-7174.2002.tb00608.x","article-title":"Using discrete choice experiments to evaluate alternative electronic prescribing systems","volume":"10","author":"Ubach","year":"2002","journal-title":"Int J Pharm Pract"},{"key":"2025120618151337000_6.2.e009387.29","doi-asserted-by":"publisher","DOI":"10.1007\/s11116-013-9451-z"},{"key":"2025120618151337000_6.2.e009387.30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1755-5345(13)70014-9","article-title":"Discrete choice experiments are not conjoint analysis","volume":"3","author":"Louviere","year":"2010","journal-title":"J Choice Model"},{"key":"2025120618151337000_6.2.e009387.31","unstructured":"Kj\u00e6r T . A review of the discrete choice experiment\u2014with emphasis on its application in health care. Health Economics Papers #1, University of Southern Denmark, 2005."},{"key":"2025120618151337000_6.2.e009387.32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1472-6963-10-197","article-title":"Criteria for priority setting of HIV\/AIDS interventions in Thailand: a discrete choice experiment","volume":"10","author":"Youngkong","year":"2010","journal-title":"BMC Health Serv Res"},{"key":"2025120618151337000_6.2.e009387.33","unstructured":"Beelaerts van Blokland R . Designing stated choice experiments: an analysis of the effects of airport location on air passenger's travel choice. Delft: Delft University of Technology, 2008."},{"key":"2025120618151337000_6.2.e009387.34","doi-asserted-by":"crossref","unstructured":"Johnson FR , Hauber AB , Gonzalez JM , et al . Patient preference weights for benefit-risk analysis: a statin case study. Poster session presented at: ISPOR 15th Annual International Meeting; 15-19 May 2010, Atlanta, GA.","DOI":"10.1016\/S1098-3015(10)72072-6"},{"key":"2025120618151337000_6.2.e009387.35","doi-asserted-by":"crossref","unstructured":"Gonzalez JM , Johnson FR , Fairchild AO , et al . Patients at the center of regulatory decisions: using stated-preference data to help regulators answer difficult questions. Poster session presented at: ISPOR 16th Annual European Congress; 2\u20136 Nov 2013, Dublin, Ireland.","DOI":"10.1016\/j.jval.2013.08.370"},{"key":"2025120618151337000_6.2.e009387.36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111066"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-009387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:15:21Z","timestamp":1765073721000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-009387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,25]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1136\/bmjopen-2015-009387"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-009387","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}